Baxter International vs Boston Scientific
BAX and BSX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BAX and BSX compare
Boston Scientific is the larger company, worth 5.1 times as much as Baxter International ($60.8B against $11.9B).
Boston Scientific grew revenue faster over the last twelve months (13.5% versus 5.3% for Baxter International).
Baxter International pays a dividend yielding 0.17%; Boston Scientific does not pay one.
Boston Scientific scores higher on the StockData Score (14 against 11 for Baxter International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BAX | BSX |
|---|---|---|
| Size and price | ||
| Market cap | $11.9B | $60.8B |
| Share price | $23.00 | $41.98 |
| Change, 1 year | 2.6% | −58.1% |
| Change, 5 years | −70.5% | −2.7% |
| Beta (5Y) | 0.81 | 0.77 |
| Employees | 38K | 59K |
| StockData Score | ||
| Total score | 11 | 14 (better) |
| Valuation score | 3 | 6 (better) |
| Growth score | 1 | 4 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 4 (better) | 3 |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/E | – | 17.0× |
| P/S | 1.0× (better) | 2.9× |
| P/B | 1.8× (better) | 2.4× |
| EV/EBITDA | 14.6× | 13.1× (better) |
| P/FCF | – | 16.8× |
| PEG | – | 0.27 |
| FCF yield | – | 6.0% |
| Fair value | $24.60 | $93.08 |
| Margin of safety | 6.5% | 54.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.3% | 13.5% (better) |
| Revenue growth, 5Y average | −0.75% | 15.2% (better) |
| EPS growth (TTM) | – | 47.0% |
| Profitability | ||
| Gross margin | 30.1% | 69.9% (better) |
| Operating margin | −1.9% | 19.8% (better) |
| Net margin | −6.2% | – |
| FCF margin | – | 17.3% |
| Return on equity | −10.5% | – |
| Return on invested capital | −3.0% | 11.2% (better) |
| Financial health | ||
| Debt / equity | 0.13 (better) | 0.51 |
| Net debt / EBITDA | −1.54 | 2.17 (better) |
| Interest coverage | −0.8× | 11.4× (better) |
| Current ratio | 1.79 (better) | 1.24 |
| Altman Z-score | 2.31 | 2.87 (better) |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Dividend yield | 0.17% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −11.4% | – |
| Shareholder yield | 0.17% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 108% | 92.1% |
| Held by insiders | 0.58% | 0.19% |
| Insider net buying, 12 months | – | −$13.0M |
| Superinvestors holding | 2 (better) | 1 |
| Short interest, % of float | 4.7% | 2.9% |
Go deeper
- BAX stock overview
- BAX income statement
- BAX valuation and score
- BSX stock overview
- BSX income statement
- BSX valuation and score
Other comparisons
- BAX vs BDX
- BAX vs MDT
- BAX vs RMD
- BAX vs SOLV
- BAX vs SYK
- BDX vs BSX
- BSX vs GEHC
- BSX vs MDLN
- BSX vs MDT
- BSX vs MMM
- BSX vs SYK
For information only, not investment advice. Check the source filings before relying on any figure.